• > CJD
DHSSPS is an Accredited Investor in People Organisation

Health Protection - Creutzfeldt-Jakob Disease (CJD)

What is CJD?

Creutzfeldt-Jakob Disease (CJD) in its classical form was first described in the 1920s and is predominantly (85% of cases) a sporadic disease, with no identifiable cause. It is a rare disease and occurs worldwide at a similar rate of about 0.5 – 1 case per million of the population per year. Approximately 14% of cases are associated with gene mutations (known as familial CJD). Less than 1% of cases are iatrogenic (accidentally transmitted from one patient to another as a result of medical interventions). In sporadic cases the average age at onset is between 55 and 75, although younger patients are found in iatrogenic and familial cases.
In 1996 the National CJD Surveillance Unit in Edinburgh identified a previously unrecognised disease pattern, New Variant CJD, now known just as Variant CJD (vCJD). vCJD is a similar neuro-degenerative disease to CJD, however, the peak incidence is much lower (around age 27) and at post mortem examination the brain tissue displays a significantly different pattern under the microscope.

Frequently asked questions

Statistics on the numbers of cases of CJD are published monthly
Department of Health monthly figures

Expert Committees

A number of expert committeesLink to an external website provide advice to the Department on CJD and BSE issues  including:
  • Spongiform Encephalopathy Advisory Committee.
  • Joint Working Group.
  • CJD Incidents Panel.
  • CJD Therapy Advisory Group.

Guidance documents and professional letters

For more information go to the Department of Health guidance documentsLink to an external website.

21st May 2001

Guidance on local reporting of Creutzfeldt-Jakob Disease (CJD) and local action by Consultants in Communicable Disease Control (CsCDC).
This document describes a system for reporting cases of CJD to Consultants in Communicable Disease Control and their equivalents in the UK.

9th April 2001

Protocol for the investigation of Geographically Associated Cases of variant Creutzfeldt-Jakob Disease.
This document describes a system for investigating geographically associated cases of vCJD.

24th January 2001

November 2000

April 2000

Variant Creutzfeldt-Jakob Disease (vCJD): Advice to Practitioners of Complementary and Alternative Medicine.

9th November 1999

  • HSS(MD)16/99. Controls Assurance in Infection Control: Decontamination of medical devices.

13th August 1999

BSE, (Bovine Spongiform Encephalopathy), Background and general occupational guidance

Advisory Committee on Dangerous Pathogens HSE, 1996
ISBN 0 7176 1212 0
Price: £5.50

Transmissible Spongiform Encephalopathies – a summary of present knowledge and research

Spongiform Encephalopathy Advisory Committee
MSO 1995
ISBN 0 11 242 9874
£35.00

Precautions for work with human and animal Transmissible Spongiform Encephalopathies

Advisory Committee on Dangerous Pathogens
HMSO, 1994
ISBN 0 11 321805 2
Price £6.50.
Quick Links